Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Trontinemab is currently being studied in the Phase Ib/IIa Brainshuttle AD study assessing the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of trontinemab in participants with ...

When these cells were exposed to amyloid beta, a toxic protein linked to Alzheimer’s ... Interestingly, semaglutide did not appear to increase the number of glucagon-like peptide-1 receptors in the ...

Alzheimer's Disease (AD) is characterized by a host of recognizable cognitive symptoms, but many non-cognitive symptoms like ...

Alzheimer’s disease is characterized by a host of recognizable cognitive symptoms, but many non-cognitive symptoms like changes in sleep, anxiety and depression can be early signs of the disease.

The brain's cholesterol regulation and metabolism mechanisms may make some neurons more vulnerable to damage in the early ...

Medically reviewed by Femi Aremu, PharmD Dementia is a loss of brain function that affects memory, thinking, judgment, behavior, and language. Alzheimer's disease is the most common type of dementia.